{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-033053","form_type":"8-K","ticker":"PVCT","cik":"0000315545","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2024-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.479113+00:00","generated_at":"2026-05-31T08:44:47.507775+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Provectus converts $2.13M in director fees to Series D-1 Preferred shares","bullets":["Converted $2,131,838.75 in accrued directors’ fees into 744,878 shares of Series D-1 Preferred at $2.862 per share.","Preferred shares are convertible into 7,448,780 shares of common stock.","Issuance covers fees owed through September 30, 2024; not under 2024 Equity Compensation Plan.","Board approved on August 14, 2024; fees had been accruing since April 2017."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-033053","json":"https://secwatch.observer/filing/0001493152-24-033053.json","markdown":"https://secwatch.observer/filing/0001493152-24-033053.md","text":"https://secwatch.observer/filing/0001493152-24-033053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/315545/000149315224033053/0001493152-24-033053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315545/000149315224033053/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:44:47.507775+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}